Research on the consumption of two-component fixed combinations of medicines for the treatment of arterial hypertension in Ukraine in the period from 2020–2023 and the use of the results in the context of optimization of pharmaceutical assistance and the

Authors

DOI:

https://doi.org/10.15587/2519-4852.2025.336898

Keywords:

arterial hypertension, marketing and pharmacoeconomic research, optimization of pharmaceutical care, rational use of medicines, socio-economic accessibility, adherence to treatment

Abstract

The aim to conduct a retrospective study of the consumption of 4 groups of two-component combined drugs for the treatment of arterial hypertension and to determine the structure of their consumption by the number of tablets, , taking into account active substances and their doses, to further formulate proposals to improve the provision of medicines to consumers, in particular through the state reimbursement program "Affordable Medicines".

Materials and methods: The objects of the study were retail sales data for the period 2020-2024 on the pharmaceutical market of Ukraine for four groups of combined antihypertensive drugs. The data was provided by the Ukrainian pharmaceutical market research system "Pharmstandard" of the Morion company. The study used statistical and mathematical methods, as well as content analysis, comparative, logical, and systemic analysis, and data generalization.

Results: showed that combined drugs of ACE inhibitors and diuretics are the most consumed among all two-component combined drugs for the treatment of hypertension in Ukraine in 2020–2023. By median share of consumption, the following fixed-dose combinations of captopril/HCTZ (50 mg/25 mg) median 29.04%; enalapril/HCTZ (10 mg/25 mg) median 11.74%; lisinopril/HCTZ (10 mg/12.5 mg) median 11.64% and perindopril tertbutylamine with indapamide (8mg/2.5mg) –11.42% among ACE inhibitors and diuretics combinations; valsartan/HCTZ (160 mg/12.5 mg (median 40.02%); and 80 mg/12.5 mg (median 29.07%); losartan/HCTZ (50mg/12.5mg) median 11.30% among ARB and diuretic combinations; lisinopril/amlodipine (5mg/5mg) median 15.25%; and (10mg/5mg) median 11.98% perindopril arginine and amlodipine (5mg/5mg) median 13.77%; and perindopril tertbutylamine and amlodipine (4mg/5mg) median 11.08%; of all combinations of ACE inhibitors and CCBs; ; and valsartan/amlodipine, in all three available doses (160mg/5mg, 80mg/5mg and 160mg/10mg) median 43.71%; 31.36% and 20.32% respectively, among the combinations of ARBs and CCBs had the highest median consumption share in each respective group of combination drugs and were used by patients for the treatment of hypertension in Ukraine in 2020-2024.

Conclusion: Retail sales results showed that combined drugs of ACE inhibitors and diuretics, as well as combined drugs of ARBs and diuretics, are the most consumed among all two-component combined drugs for the treatment of hypertension in Ukraine in 2020-2023. Further analysis of the structure of consumption of fixed-dose combinations, considering active substances and their doses, made it possible to determine within each study group those fixed doses that have the highest median consumption share values over four years.

It is regarding them that we propose conducting further clinical and economic studies on their use in the context of discussing the issue of expanding the list of combined drugs for the treatment of hypertension that are subject to reimbursement in Ukraine

Author Biographies

Anton Gonchar, Bogohomolets National Medical University

PhD Student

Department of Organization and Economy of Pharmacy

Natalia Sholoiko, Bogohomolets National Medical University

PhD, Associate Professor

Department of Organization and Economy of Pharmacy

Kostyantyn Kosyachenko, Bogohomolets National Medical University

Doctor of Pharmaceutical Sciences, Рrofessor, Head of Department

Department of Organization and Economy of Pharmacy

Oleksandr Komarida, Bogohomolets National Medical University

PhD Student

Department of Organization and Economy of Pharmacy

References

  1. Nguyen, T. N., Chow, C. K. (2021). Global and national high blood pressure burden and control. The Lancet, 398 (10304), 932–933. https://doi.org/10.1016/s0140-6736(21)01688-3
  2. Husain, M. J., Datta, B. K., Kostova, D., Joseph, K. T., Asma, S., Richter, P. et al. (2020). Access to Cardiovascular Disease and Hypertension Medicines in Developing Countries: An Analysis of Essential Medicine Lists, Price, Availability, and Affordability. Journal of the American Heart Association, 9 (9). https://doi.org/10.1161/jaha.119.015302
  3. Geldsetzer, P., Manne-Goehler, J., Marcus, M.-E., Ebert, C., Zhumadilov, Z., Wesseh, C. S. et al. (2019). The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1·1 million adults. The Lancet, 394 (10199), 652–662. https://doi.org/10.1016/s0140-6736(19)30955-9
  4. Chow, C. K. (2013). Prevalence, Awareness, Treatment, and Control of Hypertension in Rural and Urban Communities in High-, Middle-, and Low-Income Countries. JAMA, 310 (9), 959. https://doi.org/10.1001/jama.2013.184182
  5. Rodgers, A., Chow, C. K., Jackson, R. T., Patel, A., Usherwood, T. (2017). Guideline for the diagnosis and management of hypertension in adults – 2016. Medical Journal of Australia, 206 (3), 141–141. https://doi.org/10.5694/mja16.01057
  6. Tiffe, T., Wagner, M., Rücker, V., Morbach, C., Gelbrich, G., Störk, S., Heuschmann, P. U. (2017). Control of cardiovascular risk factors and its determinants in the general population– findings from the STAAB cohort study. BMC Cardiovascular Disorders, 17 (1). https://doi.org/10.1186/s12872-017-0708-x
  7. Gupta, P., Patel, P., Štrauch, B., Lai, F. Y., Akbarov, A., Gulsin, G. S. et al. (2017). Biochemical Screening for Nonadherence Is Associated With Blood Pressure Reduction and Improvement in Adherence. Hypertension, 70 (5), 1042–1048. https://doi.org/10.1161/hypertensionaha.117.09631
  8. Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M. et al. (2018). 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, 39 (33), 3021–3104. https://doi.org/10.1093/eurheartj/ehy339
  9. Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A. et al. (2023). 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension. Journal of Hypertension, 41 (12), 1874–2071. https://doi.org/10.1097/hjh.0000000000003480
  10. McEvoy, J. W., McCarthy, C. P., Bruno, R. M., Brouwers, S., Canavan, M. D., Ceconi, C. et al. (2024). 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. European Heart Journal, 45 (38), 3912–4018. https://doi.org/10.1093/eurheartj/ehae178
  11. Pro vnesennia zmin do nakazu Ministerstva okhorony zdorovia Ukrainy vid 28 veresnia 2012 roku No. 751. (2016). Nakaz Ministerstva okhorony zdorovia Ukrainy No. 1422. 29.12.2016. Available at: https://zakon.rada.gov.ua/laws/show/z0530-17#Text
  12. Roth, G. A., Mensah, G. A., Johnson, C. O., Addolorato, G., Ammirati, E., Baddour, L. M. et al. (2020). Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019. Journal of the American College of Cardiology, 76 (25), 2982–3021. https://doi.org/10.1016/j.jacc.2020.11.010
  13. Jamison, D. T., Summers, L. H., Alleyne, G., Arrow, K. J., Berkley, S., Binagwaho, A. et al. (2013). Global health 2035: a world converging within a generation. The Lancet, 382 (9908), 1898–1955. https://doi.org/10.1016/s0140-6736(13)62105-4
  14. Su, M., Zhang, Q., Bai, X., Wu, C., Li, Y., Mossialos, E. et al. (2017). Availability, cost, and prescription patterns of antihypertensive medications in primary health care in China: a nationwide cross-sectional survey. The Lancet, 390 (10112), 2559–2568. https://doi.org/10.1016/s0140-6736(17)32476-5
  15. Attaei, M. W., Khatib, R., McKee, M., Lear, S., Dagenais, G., Igumbor, E. U. et al. (2017). Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: an analysis of the PURE study data. The Lancet Public Health, 2 (9), e411–e419. https://doi.org/10.1016/s2468-2667(17)30141-x
  16. Huz, V. S., Zaliska, O. M., Maksymovych, N. M. (2020). Retrospective analysis of prescriptions for the treatment of cardiovascular diseases in the program «Affordable medicines» on the example of a pharmacy. Farmatsevtychnyi Zhurnal, 3, 69–79. https://doi.org/10.32352/0367-3057.3.20.07
  17. Piniazhko, O., Zaliska, O., Ilyk, R. (2018). Reimbursement Decision-Making in Ukraine: Current and Future Directions. Value in Health, 21, S107. https://doi.org/10.1016/j.jval.2018.04.728
  18. Elektronni retsepty na likarski zasoby: vypysuvannia ta vidpusk. Natsionalna sluzhba zdorovia Ukrainy. Available at: https://edata.e-health.gov.ua/e-data/dashboard/reimb-prescription-details
  19. Medicines reimbursement policies in Europe (2018). WHO. Available at: https://www.who.int/europe/publications/i/item/9789289053365
  20. Huz, V. S., Zaliska, O. M. (2019). Analysis of dynamics of the drug list in the аffordable medicines program for treatment of cardiovascular diseases. Farmatsevtychnyi Zhurnal, 3, 21–30. https://doi.org/10.32352/0367-3057.3.19.03
  21. eEML – Electronic Essential Medicines List (2019). World Health Organisation. Available at: https://list.essentialmeds.org/?section=&indication=139&year=2019&age=&sex=
  22. Pro vnesennia zmin do postanovy Kabinetu Ministriv Ukrainy vid 25 bereznia 2009 r. No. 333 (2024). Postanova Kabinetu Ministriv Ukrainy No. 733. 21.06.2024. Available at: https://zakon.rada.gov.ua/go/733-2024-%D0%BF
  23. Deiaki pytannia dostupnosti likarskykh zasobiv, shcho pidliahaiut reimbursatsii u 2025 rotsi. (2024). Postanova Kabinetu Ministriv Ukrainy No. 1380. 03.12.2024. Available at: https://zakon.rada.gov.ua/laws/show/1380-2024-%D0%BF#Text
  24. Pro vnesennia zmin do Natsionalnoho pereliku osnovnykh likarskykh zasobiv. (2024). Postanova Kabinetu Ministriv Ukrainy No. 1296. 12.11.2024. Available at: https://zakon.rada.gov.ua/laws/show/1296-2024-%D0%BF#Text
  25. Salam, A., Huffman, M. D., Kanukula, R., Hari Prasad, E., Sharma, A., Heller, D. J. et al. (2020). Two‐drug fixed‐dose combinations of blood pressure‐lowering drugs as WHO essential medicines: An overview of efficacy, safety, and cost. The Journal of Clinical Hypertension, 22 (10), 1769–1779. https://doi.org/10.1111/jch.14009
  26. WHOCC – Guidelines. 2022 Guidelines for ATC Classification and DDD Assigment (2021). WHO Collaboration Center for Drugs Statistics Methodology. Available at: https://www.whocc.no/atc_ddd_index_and_guidelines/guidelines/
  27. Doslidzhennia farmatsevtychnoho rynku Ukrainy analitychnoi kompanii “Farmstandart” kompanii “Morion”. Available at: http://pharmstandart.com.ua
  28. Derzhavnyi reiestr likarskykh zasobiv Ukrainy. Available at: http://www.drlz.com.ua/
  29. Sholoiko, N. V., Honchar, A. O. (2022). Comparative analysis of the range list of medicines for the treatment of arterial hypertension in accordance with domestic and international clinical guidelines. Farmatsevtychnyi Zhurnal, 1, 31–39. https://doi.org/10.32352/0367-3057.1.22.03
  30. Osnovy statystyky ta analizu danykh. Ukrainskyi tsentr suspilnykh danykh. Available at: https://socialdata.org.ua/manual/manual4/
  31. Lee, Y., Shin, J., Kim, Y., Kim, D.-S. (2021). Consumption of single products versus fixed-dose combination medicines for hypertension and hyperlipidemia during 2015–2019 in South Korea. PLOS ONE, 16 (12), e0259467. https://doi.org/10.1371/journal.pone.0259467
  32. Ishida, T., Oh, A., Nishigaki, N., Tsuchihashi, T. (2019). Treatment patterns of antihypertensive fixed‐dose combinations according to age and number of agents prescribed: Retrospective analysis using a Japanese claims database. Geriatrics & Gerontology International, 19 (11), 1077–1083. https://doi.org/10.1111/ggi.13743
  33. Pro zatverdzhennia poriadku vkliuchennia (vykliuchennia) likarskykh zasobiv do (z) Natsionalnoho pereliku osnovnykh likarskykh zasobiv ta/abo do (z) nomenklatury likarskykh zasobiv, shcho zakupovuiutsia za koshty derzhavnoho biudzhetu dlia vykonannia prohram zdiisnennia tsentralizovanykh zakhodiv z okhorony zdorovia, iz zastosuvanniam derzhavnoi otsinky medychnykh tekhnolohii (2022). Nakaz MOZ No. 4. 04.01.2022. Available at: https://zakon.rada.gov.ua/laws/show/z0095-22#Text
  34. Pro zatverdzhennia Poriadku provedennia derzhavnoi otsinky medychnykh tekhnolohii (2020). Postanova KMU No. 1300. 23.12.2020. Available at: https://zakon.rada.gov.ua/laws/show/1300-2020-%D0%BF#Text
Research on the consumption of two-component fixed combinations of medicines for the treatment of arterial hypertension in Ukraine in the period from 2020–2023 and the use of the results in the context of optimization of pharmaceutical assistance and the

Downloads

Published

2025-08-30

How to Cite

Gonchar, A., Sholoiko, N., Kosyachenko, K., & Komarida, O. (2025). Research on the consumption of two-component fixed combinations of medicines for the treatment of arterial hypertension in Ukraine in the period from 2020–2023 and the use of the results in the context of optimization of pharmaceutical assistance and the . ScienceRise: Pharmaceutical Science, (4 (56), 4–19. https://doi.org/10.15587/2519-4852.2025.336898

Issue

No. 4 (56) (2025)

Section

Pharmaceutical Science

License

Copyright (c) 2025 Anton Gonchar, Natalia Sholoiko, Kostyantyn Kosyachenko, Oleksandr Komarida

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.